603087 甘李药业
已收盘 07-03 15:00:00
资讯
新帖
简况
7月3日甘李药业涨6.53%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 07-03 16:28
7月3日甘李药业涨6.53%，招商国证生物医药指数(LOF)C基金重仓该股
甘李药业涨6.53%，国金证券二个月前给出“买入”评级
证券之星 · 07-03 16:28
甘李药业涨6.53%，国金证券二个月前给出“买入”评级
6月29日甘李药业涨7.07%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 06-29
6月29日甘李药业涨7.07%，招商国证生物医药指数(LOF)C基金重仓该股
甘李药业涨7.07%，国金证券二个月前给出“买入”评级
证券之星 · 06-29
甘李药业涨7.07%，国金证券二个月前给出“买入”评级
甘李药业（603087）披露2026年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票自查报告，6月26日股价下跌5.15%
证券之星 · 06-26
甘李药业（603087）披露2026年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票自查报告，6月26日股价下跌5.15%
甘李药业最新公告：甘精胰岛素注射液获洪都拉斯药品注册批件
证券之星 · 06-26
甘李药业最新公告：甘精胰岛素注射液获洪都拉斯药品注册批件
甘李药业：总部园区内设有图书馆
证券之星 · 06-25
甘李药业：总部园区内设有图书馆
甘李药业：公司已于2026年6月11日正式披露了《2026年限制性股票激励计划（草案）》
证券之星 · 06-25
甘李药业：公司已于2026年6月11日正式披露了《2026年限制性股票激励计划（草案）》
甘李药业：公司高度重视信息披露的合规性
证券之星 · 06-25
甘李药业：公司高度重视信息披露的合规性
甘李药业：公司将持续深化渠道下沉，让优质产品惠及更多患者
证券之星 · 06-25
甘李药业：公司将持续深化渠道下沉，让优质产品惠及更多患者
甘李药业：公司紧抓胰岛素接续采购政策机遇，推动商业化网络提质扩容
证券之星 · 06-25
甘李药业：公司紧抓胰岛素接续采购政策机遇，推动商业化网络提质扩容
甘李药业（603087）披露2026年限制性股票激励计划激励对象名单核查意见，6月22日股价上涨0.49%
证券之星 · 06-22
甘李药业（603087）披露2026年限制性股票激励计划激励对象名单核查意见，6月22日股价上涨0.49%
甘李药业(603087.SH)：甘精胰岛素注射液(预填充笔)获得阿联酋药品注册批件
智通财经 · 06-18
甘李药业(603087.SH)：甘精胰岛素注射液(预填充笔)获得阿联酋药品注册批件
甘李药业（603087）329.87万股限售股将于6月17日解禁，占总股本0.55%
证券之星 · 06-17
甘李药业（603087）329.87万股限售股将于6月17日解禁，占总股本0.55%
甘李药业胰岛素Ludefen (Gzr4)在中国III期试验中达到主要终点
美股速递 · 06-12
甘李药业胰岛素Ludefen (Gzr4)在中国III期试验中达到主要终点
甘李药业周制剂胰岛素鲁德芬展现良好安全性，无严重低血糖事件
美股速递 · 06-12
甘李药业周制剂胰岛素鲁德芬展现良好安全性，无严重低血糖事件
甘李药业(603087.SH)拟推2026年限制性股票激励计划
智通财经 · 06-10
甘李药业(603087.SH)拟推2026年限制性股票激励计划
每周股票复盘：甘李药业（603087）股东部分股份解押完成
证券之星 · 06-07
每周股票复盘：甘李药业（603087）股东部分股份解押完成
甘李药业（603087）披露持股5%以上股东部分股份解押公告，6月2日股价上涨4.33%
证券之星 · 06-02
甘李药业（603087）披露持股5%以上股东部分股份解押公告，6月2日股价上涨4.33%
甘李药业：2025年国际销售收入达5.29亿元
证券之星 · 06-02
甘李药业：2025年国际销售收入达5.29亿元
加载更多
公司概况
公司名称：
甘李药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-29
主营业务：
甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。
发行价格：
63.32
{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":60.99,"timestamp":1783062001000,"preClose":57.25,"halted":0,"volume":18502549,"delay":0,"changeRate":0.0653,"floatShares":561000000,"shares":597000000,"eps":1.7147,"marketStatus":"已收盘","change":3.74,"latestTime":"07-03 15:00:00","open":57.93,"high":62.44,"low":57.61,"amount":1113000000,"amplitude":0.0844,"askPrice":60.99,"askSize":153,"bidPrice":60.98,"bidSize":1,"shortable":0,"etf":0,"ttmEps":1.7147,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":57.25,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":62.98,"lowLimit":51.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597304969,"isCdr":false,"pbRate":3.08,"roa":"--","peRate":35.568904,"roe":"1.64%","epsLYR":1.93,"committee":-0.969427,"marketValue":36430000000,"turnoverRate":0.033,"status":0,"floatMarketCap":34225000000},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2648765415","title":"7月3日甘李药业涨6.53%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648765415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648765415?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:28","pubTimestamp":1783067331,"startTime":"0","endTime":"0","summary":"证券之星消息，7月3日甘李药业涨6.53%，收盘报60.99元，换手率3.3%，成交量18.5万手，成交额11.13亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共42家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.1亿元，最新净值0.3762，较上一交易日下跌1.1%，近一年下跌1.78%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300029610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","BK0239","399441","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648542396","title":"甘李药业涨6.53%，国金证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648542396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648542396?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:28","pubTimestamp":1783067319,"startTime":"0","endTime":"0","summary":"今日甘李药业涨6.53%，收盘报60.99元。2026年4月23日，国金证券研究员甘坛焕,马居东发布了对甘李药业的研报《25年业绩高增，研发及出海加速》，该研报对甘李药业给出“买入”评级。维持“买入”评级证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为77.02%。甘李药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300029595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647432497","title":"6月29日甘李药业涨7.07%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647432497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647432497?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:32","pubTimestamp":1782721934,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日甘李药业涨7.07%，收盘报57.57元，换手率2.45%，成交量13.73万手，成交额7.75亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共42家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.1亿元，最新净值0.3461，较上一交易日下跌2.42%，近一年下跌7.34%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239","399441","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647244863","title":"甘李药业涨7.07%，国金证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647244863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647244863?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:32","pubTimestamp":1782721925,"startTime":"0","endTime":"0","summary":"今日甘李药业涨7.07%，收盘报57.57元。2026年4月23日，国金证券研究员甘坛焕,马居东发布了对甘李药业的研报《25年业绩高增，研发及出海加速》，该研报对甘李药业给出“买入”评级。维持“买入”评级证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为77.02%。甘李药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646637773","title":"甘李药业（603087）披露2026年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票自查报告，6月26日股价下跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646637773","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646637773?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:23","pubTimestamp":1782483802,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，甘李药业报收于53.77元，较前一交易日下跌5.15%，最新总市值为321.17亿元。公告显示，公司对2026年限制性股票激励计划内幕信息知情人及激励对象在草案公告日前六个月内买卖公司股票的情况进行了自查。核查期间为2025年12月11日至2026年6月11日，通过中国证券登记结算有限责任公司上海分公司查询，部分激励对象存在少量股票买卖行为，但公司确认其未利用内幕信息进行交易。公司已采取必要保密措施，未发现信息泄露情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600045628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646635618","title":"甘李药业最新公告：甘精胰岛素注射液获洪都拉斯药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2646635618","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646635618?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:10","pubTimestamp":1782468618,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司收到洪都拉斯国家药品监督管理局核准签发的甘精胰岛素注射液注册批件，该药品适应症为糖尿病。截至2026年3月31日，公司在该项目中累计投入研发费用9.44亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600034508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646759868","title":"甘李药业：总部园区内设有图书馆","url":"https://stock-news.laohu8.com/highlight/detail?id=2646759868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646759868?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:57","pubTimestamp":1782377860,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业06月25日在投资者关系平台上答复投资者关心的问题。在人才培养方面，甘李药业为不同职业发展阶段的员工设计并实施了专项培养项目，包括“小新甘”新员工融入计划、继任者人才项目、未来领袖计划等，为员工提供系统、全面的学习发展平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500030310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646756758","title":"甘李药业：公司已于2026年6月11日正式披露了《2026年限制性股票激励计划（草案）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2646756758","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646756758?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:57","pubTimestamp":1782377859,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业06月25日在投资者关系平台上答复投资者关心的问题。甘李药业回复：尊敬的投资者您好，公司已于2026年6月11日正式披露了《2026年限制性股票激励计划（草案）》《2026年限制性股票激励计划激励对象名单》 ，目前推进实施中，后续进展请持续关注公司的公告。公司已连续三次荣获“福布斯中国最佳雇主”奖项，并在2025年入选“福布斯中国年度最受员工欢迎雇主”榜单。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500030309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646875938","title":"甘李药业：公司高度重视信息披露的合规性","url":"https://stock-news.laohu8.com/highlight/detail?id=2646875938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646875938?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:57","pubTimestamp":1782377849,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业06月25日在投资者关系平台上答复投资者关心的问题。您的建议与提醒是对公司持续完善信息披露工作的重要鞭策，我们会向管理层反馈，持续加强信息披露合规培训，避免不必要的合规风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500030305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646875674","title":"甘李药业：公司将持续深化渠道下沉，让优质产品惠及更多患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2646875674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646875674?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:57","pubTimestamp":1782377847,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业06月25日在投资者关系平台上答复投资者关心的问题。公司将持续深化渠道下沉，让优质产品惠及更多患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500030302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646759808","title":"甘李药业：公司紧抓胰岛素接续采购政策机遇，推动商业化网络提质扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2646759808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646759808?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:57","pubTimestamp":1782377847,"startTime":"0","endTime":"0","summary":"借助集采形成的渠道优势，公司实现各层级医疗终端深度覆盖，三代胰岛素渗透率持续提升，锐秀霖、锐秀霖30 等核心产品快速放量，销量实现显著增长。公司通过两轮胰岛素集采，成功实现扩大市场份额的战略目标。胰岛素周制剂有望显著提高患者的依从性和生活质量，并带来更加持久有效、平稳无峰的血糖控制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500030300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645507395","title":"甘李药业（603087）披露2026年限制性股票激励计划激励对象名单核查意见，6月22日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645507395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645507395?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:33","pubTimestamp":1782138801,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，甘李药业报收于56.98元，较前一交易日上涨0.49%，最新总市值为340.34亿元。公告显示，公司于2026年6月11日至6月21日在内部OA系统公示了2026年限制性股票激励计划激励对象名单，公示期间未收到任何异议。董事会薪酬与考核委员会认为，激励对象名单符合规定，主体资格合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200039014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644970934","title":"甘李药业(603087.SH)：甘精胰岛素注射液(预填充笔)获得阿联酋药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2644970934","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644970934?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:58","pubTimestamp":1781773125,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，近日，公司欧洲全资子公司甘李药业欧洲有限责任公司收到阿拉伯联合酋长国药品管理局(EDE)核准签发的甘精胰岛素注射液(预填充笔)注册批件。甘精胰岛素为基础长效胰岛素，每天皮下注射一次，降糖作用时间持续24小时。其具有作用时间长、血药浓度平稳无峰和平稳控糖的特点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644796295","title":"甘李药业（603087）329.87万股限售股将于6月17日解禁，占总股本0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644796295","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644796295?lang=zh_cn&edition=full","pubTime":"2026-06-17 08:13","pubTimestamp":1781655184,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，甘李药业于6月17日将有329.87万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.55%。最近一年内，该股累计解禁748.08万股，占总股本的1.25%。本次解禁后，公司还有3614.77万股限售股份，占总股本6.05%。甘李药业主营业务：胰岛素类似物原料药及注射剂研发、生产和销售。本文数据来源于甘李药业公告，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700006793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121050790","title":"甘李药业胰岛素Ludefen (Gzr4)在中国III期试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1121050790","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121050790?lang=zh_cn&edition=full","pubTime":"2026-06-12 20:03","pubTimestamp":1781265802,"startTime":"0","endTime":"0","summary":"甘李药业的胰岛素药物Ludefen (Gzr4)在中国的III期临床试验中成功达到了预设的主要研究终点。这一关键进展为这款创新药物的后续开发与商业化铺平了道路，标志着公司在糖尿病治疗领域取得了重要突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168456753","title":"甘李药业周制剂胰岛素鲁德芬展现良好安全性，无严重低血糖事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1168456753","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168456753?lang=zh_cn&edition=full","pubTime":"2026-06-12 20:03","pubTimestamp":1781265801,"startTime":"0","endTime":"0","summary":"甘李药业研发的周制剂胰岛素Ludefen（鲁德芬）在临床研究中展现出良好的安全性特征，未报告严重低血糖事件。\n该研究结果凸显了这款新型胰岛素在提供有效血糖控制的同时，对患者安全性的积极保障，为糖尿病治疗领域提供了新的潜在选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642242575","title":"甘李药业(603087.SH)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2642242575","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642242575?lang=zh_cn&edition=full","pubTime":"2026-06-10 20:18","pubTimestamp":1781093933,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)披露2026年限制性股票激励计划(草案)，此次激励计划拟向激励对象授予的限制性股票数量为63万股，约占激励计划草案公告日公司股本总额5.97亿股的0.1055%。限制性股票的授予价格为27.8元/股。激励对象共计20人，包括公司公告激励计划时在公司(含子公司，下同)任职的高级管理人员及核心技术(业务)骨干。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127894","title":"每周股票复盘：甘李药业（603087）股东部分股份解押完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127894","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127894?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:54","pubTimestamp":1780768453,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，甘李药业报收于54.58元，较上周的52.28元上涨4.4%。本周，甘李药业6月3日盘中最高价报55.95元。公司公告汇总关于公司持股5%以上股东部分股份解押的公告甘李药业股份有限公司持股5%以上股东北京旭特宏达科技有限公司持有公司股份32,073,734股，占公司总股本的5.37%。2026年6月1日，旭特宏达办理了13,110,000股股份的解押登记手续。控股股东甘忠如及其控制的旭特宏达合计持股237,717,491股，占公司总股本的39.80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640194982","title":"甘李药业（603087）披露持股5%以上股东部分股份解押公告，6月2日股价上涨4.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640194982","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640194982?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:09","pubTimestamp":1780409394,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，甘李药业报收于54.99元，较前一交易日上涨4.33%，最新总市值为328.46亿元。公告显示，公司持股5%以上股东北京旭特宏达科技有限公司持有公司股份32,073,734股，占公司总股本的5.37%。2026年6月1日，旭特宏达办理了13,110,000股股份的解押登记手续。本次解押后，旭特宏达累计质押公司股份数量为9,450,000股，占其持股数量的29.46%，占公司总股本的1.58%。控股股东甘忠如及其控制的旭特宏达合计持股237,717,491股，占公司总股本的39.80%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200047035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640919975","title":"甘李药业：2025年国际销售收入达5.29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640919975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640919975?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:19","pubTimestamp":1780391962,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业06月02日在投资者关系平台上答复投资者关心的问题。谢谢甘李药业回复：尊敬的投资者您好，2025 年中国药企迎来全球化发展的重要节点。作为国内胰岛素领域的标杆企业，公司依托二十余年的技术积累与产业深耕，已构建完整的产业价值链，并将产品商业化销售成功拓展至全球21个国家，覆盖欧亚、亚太、拉美及非洲等多个地区。2025年，国际销售收入达5.29亿元，同比增长36.59%，市场贡献稳步提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783285346012,"stockEarnings":[{"period":"1week","weight":0.1343},{"period":"1month","weight":0.1263},{"period":"3month","weight":-0.0157},{"period":"6month","weight":-0.0868},{"period":"1year","weight":0.0986},{"period":"ytd","weight":-0.0868}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"81965人(较上一季度减少5.45%)","perCapita":"6846股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59730万元","survey":" 甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}